Skip to main content
News & Press Releases

John Vacha Joins Imagin Medical Board of Directors

By 30 January 2018August 11th, 2022No Comments

Vancouver, B.C. and Boston, MA, January 30, 2018– Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that John Vacha, the Company’s recently appointed CFO, has joined Imagin’s Board of Directors, replacing William Galine, who recently resigned for health reasons. 

With over 20 years’ experience in the healthcare industry, Mr. Vacha is well versed in corporate governance and the medical device field. Prior to his appointment as Imagin’s CFO, John served as President, CEO and Board Member of Intact Medical Corporation for seven years before it was acquired by Medtronic in 2017, and previously served as the company’s Vice President, CFO and Treasurer. 

“John brings significant business management and healthcare perspective to the Board,” said Jim Hutchens, Imagin’s President and CEO. “His heath care expertise is an ideal complement to Imagin’s Board at this stage of the Company’s development.” 

John also served as Senior Consultant at Deloitte & Touche, LLP, where his clients included closely held high-tech manufacturing start-up companies, as well as large retail and manufacturing corporations. Mr. Vacha is a licensed CPA in Massachusetts, holds a MBA and a MS in Accounting from Northeastern University in Boston, Massachusetts and holds two patents in electrosurgical instrumentation. 

About Imagin Medical 

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at 

For further information, contact: 

Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: [email protected] 

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release. 

U.S. HQ: 69 Longwood Avenue CA HQ: 890 West Pender Street, Suite 600 Hyannis Port, MA 02647 Vancouver, British Columbia USA Canada V6C 1J9 617-571-6006 778-998-5000; 604-687-1327 (fax)